Insider Selling: Q32 Bio (NASDAQ:QTTB) CEO Sells $163,033.20 in Stock

Posted by Geri Gentry on Aug 30th, 2026

Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) CEO Jodie Pope Morrison sold 9,845 shares of Q32 Bio stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total transaction of $163,033.20. Following the completion of the transaction, the chief executive officer directly owned 343,259 shares in the company, valued at approximately $5,684,369.04. The trade was a 2.79% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Q32 Bio Stock Down 6.9%

Shares of QTTB stock opened at $15.03 on Friday. Q32 Bio Inc. has a 12-month low of $1.62 and a 12-month high of $23.57. The firm has a fifty day moving average of $14.90 and a 200-day moving average of $9.71. The company has a market capitalization of $447.44 million, a price-to-earnings ratio of 5.01 and a beta of 0.23.

Q32 Bio (NASDAQ:QTTB – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.02. On average, equities analysts expect that Q32 Bio Inc. will post -1.51 EPS for the current year.

Institutional Trading of Q32 Bio

Several institutional investors and hedge funds have recently bought and sold shares of QTTB. Marshall Wace LLP bought a new position in Q32 Bio in the second quarter valued at approximately $25,000. ADAR1 Capital Management LLC bought a new stake in shares of Q32 Bio during the 4th quarter worth approximately $66,000. XTX Topco Ltd acquired a new stake in shares of Q32 Bio in the 4th quarter valued at approximately $68,000. Cetera Investment Advisers acquired a new stake in shares of Q32 Bio in the 1st quarter valued at approximately $133,000. Finally, Susquehanna International Group LLP bought a new position in shares of Q32 Bio in the second quarter valued at $297,000. Institutional investors own 31.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on QTTB. HC Wainwright increased their price objective on Q32 Bio from $13.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Morgan Stanley initiated coverage on Q32 Bio in a research note on Monday, August 24th. They issued an “overweight” rating and a $34.00 target price on the stock. Zacks Research downgraded Q32 Bio from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Cantor Fitzgerald initiated coverage on shares of Q32 Bio in a research note on Monday, May 18th. They set an “overweight” rating for the company. Finally, Mizuho began coverage on shares of Q32 Bio in a report on Friday, May 22nd. They issued an “outperform” rating and a $14.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Q32 Bio has an average rating of “Moderate Buy” and a consensus target price of $31.00.

Read Our Latest Report on Q32 Bio

Q32 Bio Company Profile

(Get Free Report)

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.